about
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group StudyPhase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasiaRandomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyPhase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group studyRelationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group StudyPhase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
P50
Q30389289-3BC76197-1F13-4A91-851B-90CF663E21A2Q30407709-11FC1456-78AE-4E02-B054-5CCF00E06D02Q30439393-4EE1AC7D-EA6B-4C43-992B-70F093A83F54Q33898174-14223DAE-19C8-48A2-ACAC-4A6EE3BBFF4FQ34743475-7D11E223-EA0B-45A8-B705-B4A26BD81B2EQ37809370-7D9BB0DD-D0B6-47BB-92A5-CEF98E78A8EAQ40616141-2D0B278F-8A28-4CA7-96E7-71314B638EA4Q44812246-56683CFD-A6E4-42C4-BDDE-F3092C55A3F4Q58964122-4C47EECC-2A47-4CFB-A1CC-412AE8E7E263Q58964151-6376C4DE-6E73-4E2F-A386-23FECB5BA070Q58964184-C932E7E3-63F1-456B-98B4-522356FFE62BQ58964242-692C5D17-08E5-4606-A9DE-3F54ECF099C1Q80390603-69BC78AF-7BE5-4A56-8E2A-0820B85C0169Q92622163-C0398EA4-830A-490F-840A-4F5F2BDB2E76
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Virginia Filiaci
@ast
Virginia Filiaci
@en
Virginia Filiaci
@es
Virginia Filiaci
@nl
Virginia Filiaci
@sl
type
label
Virginia Filiaci
@ast
Virginia Filiaci
@en
Virginia Filiaci
@es
Virginia Filiaci
@nl
Virginia Filiaci
@sl
altLabel
Virginia Brunetto
@en
prefLabel
Virginia Filiaci
@ast
Virginia Filiaci
@en
Virginia Filiaci
@es
Virginia Filiaci
@nl
Virginia Filiaci
@sl
P106
P1153
14630264200
P21
P31
P3835
virginia-filiaci
P496
0000-0002-0623-9667